On August 30, 2018 Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, reported that senior management will present at the following upcoming investor conferences (Press release, Immune Design, AUG 30, 2018, View Source [SID1234529181]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

13th Annual Wells Fargo Securities Healthcare Conference
Wednesday, September 5, 2018 at 1:50 p.m. Eastern Time in Boston.

H.C. Wainwright & Co. 20th Annual Global Investment Conference
Thursday, September 6, 2018 at 10:50 a.m. Eastern Time in New York.

A live webcast of each presentation will be available online from the investor relations page of the company’s corporate website at View Source After the live webcast, an archive of each presentation will be available on the company website for 30 days.

On August 30, 2018 Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, reported that Derek Maetzold, President and CEO, will present at the Baird Global Healthcare Conference on Wednesday, September 5th, 2018 at 11:25 a.m. ET in New York City (Press release, Castle Biosciences, AUG 30, 2018, View Source [SID1234529198]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 30, 2018 Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, reported that new proof-of-concept preliminary data from its ongoing China clinical study evaluating ET140202 for the treatment of AFP-positive hepatocellular carcinoma (AFP+ HCC) will be presented as a late-breaking oral presentation at the 4th Annual CAR-TCR Summit in Boston, Massachusetts, September 4-7, 2018 (Press release, Eureka Therapeutics, AUG 30, 2018, View Source [SID1234529199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation details are listed below and are accessible on the 4th Annual CAR-TCR Summit website:

Presentation Title: Case Report of Regression of Metastatic Liver Cancer After ET140202 T-Cell Therapy
Session Title: Late Breaking Abstracts
Date & Time: Wednesday, September 5, 2018 from 9:15 a.m. – 9:35 a.m. ET
Location: Seaport Hotel & World Trade Center

Presentation Title: Improvement of Safety in T-cell Immunotherapies for the Treatment of Cancer
Session Title: Overcoming CAR-T Toxicity in Solid Tumors (Agenda 1)
Date & Time: Friday, September 7, 2018 from 1:00 p.m. – 1:30 p.m. ET
Location: Seaport Hotel & World Trade Center

On August 30, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the Wells Fargo Securities 2018 Healthcare Conference in Boston (Press release, Array BioPharma, AUG 30, 2018, View Source [SID1234529222]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

Wells Fargo Securities 2018 Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Thursday, September 6, 2018

Time:

3:05 p.m. Eastern Time

Webcast:

https://cc.talkpoint.com/well001/090518a_as/?entity=47_0GHY12N

On August 30, 2018 Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications, reported it will provide an overview of the company and its programs at the 20th Annual Rodman & Renshaw Global Investment Conference (Press release, Mateon Therapeutics, AUG 30, 2018, View Source [SID1234529184]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mateon’s presentation is scheduled to occur on Thursday, September 6, 2018 at 3:00 p.m. eastern time. To listen to a live webcast of the presentation, please visit the Company’s website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at the same location following the conclusion of the live event.